Abcellera Biologics is trading at $10.82 (-4.03%) with no new company announcement or clearly reported September 2 catalyst found.
- Official releases show the latest listed 2026 news predates this session.
- Earlier financing pressure may remain relevant: AbCellera priced a $200 million offering at $9.75 per share, previously linked to dilution concerns.
- The decline is notable as biotech and major indexes are higher.